Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

These 173 leaders will help steer the firm as Wall Street readies for a potential flood of dealmaking, from M&A to IPOs.

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 ...

The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

Investment banking revenues soared at Jefferies Financial in the fourth quarter, a positive sign for Wall Street as bigger banks prepare to report their results next week.

JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...

Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Wall Street giant Morgan Stanley promoted 173 of its employees to managing director roles this year, marking a 12% increase ...

Morgan Stanley (NYSE:MS – Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, ...